Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

Author(s):

Paul Hahn, MD, PhD, FASRS,Michael Cohen, MD, FAAO

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

To watch the video series component of this episode, click here.

0:00 Introduction

1:05 Overview of faricimab and high-dose aflibercept

3:48 clinical trials for faricimab and high-dose aflibercept

9:12 Comparing the matched dose phase results in clinical trials

12:30 Potential impacts of Ang-2 inhibition

14:40 Real-world experience with faricimab

22:00 Challenges with step therapy

24:00 Choosing between faricimab vs high-dose aflibercept

29:00 Perspectives on retreatment criteria in clinical trials

33:00 Label differences between faricimab and high-dose aflibercept

35:00 Final remarks